Hormonal
GLP-1 receptor agonists (e.g., liraglutide) produce significant weight loss (up to 10 kg) in humans, primarily by reducing energy intake and increasing energy expenditure, and are currently the most promising pharmacological class for treating obesity.
GLP-1 medications like liraglutide are effective for weight loss, potentially reducing body weight by up to 10 kg over two years. They work by mimicking gut hormones that signal satiety. While they are currently used for diabetes, higher doses are being tested for obesity. Consult a doctor to see if this treatment is appropriate for your specific health profile.
there is evidence that higher doses of the GLP-1R agonist liraglutide than are necessary for glucose lowering can produce greater weight loss of up to 10 kg in trials of up to 2 years duration (Astrup et al., 2009; Astrup et al., 2011).
Why this rating
Based on Phase III trials and established clinical use in diabetes, though long-term obesity-specific data is still being finalized.
Source
Anti-obesity drugs: past, present and future
R.J. Rodgers et al. · Disease Models & Mechanisms · 2012
DOI 10.1242/dmm.009621
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →